Free Trial
NASDAQ:KZR

Kezar Life Sciences Q3 2023 Earnings Report

Kezar Life Sciences logo
$4.01 +0.03 (+0.75%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$4.08 +0.07 (+1.72%)
As of 08/8/2025 05:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Kezar Life Sciences EPS Results

Actual EPS
-$3.20
Consensus EPS
-$3.60
Beat/Miss
Beat by +$0.40
One Year Ago EPS
N/A

Kezar Life Sciences Revenue Results

Actual Revenue
$7.00 million
Expected Revenue
$0.50 million
Beat/Miss
Beat by +$6.50 million
YoY Revenue Growth
N/A

Kezar Life Sciences Announcement Details

Quarter
Q3 2023
Time
N/A
Conference Call Date
Monday, November 13, 2023
Conference Call Time
4:00PM ET

Upcoming Earnings

Kezar Life Sciences' Q2 2025 earnings is scheduled for Tuesday, August 12, 2025

Earnings Documents

Kezar Life Sciences Earnings Headlines

Kezar Life Sciences, Inc. (NASDAQ:KZR) Short Interest Update
Kezar Life Sciences Says FDA Lifts Clinical Hold
Elon’s Secret Social Security Bombshell
To All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social Security? What we just discovered in Washington will stun even the most seasoned insiders.
See More Kezar Life Sciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Kezar Life Sciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Kezar Life Sciences and other key companies, straight to your email.

About Kezar Life Sciences

Kezar Life Sciences (NASDAQ:KZR), a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

View Kezar Life Sciences Profile

More Earnings Resources from MarketBeat